Literature DB >> 8182933

Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias.

P Corradini1, G Inghirami, M Astolfi, M Ladetto, C Voena, P Ballerini, W Gu, K Nilsson, D M Knowles, M Boccadoro.   

Abstract

The role of loss or inactivation of the retinoblastoma (Rb1) and p53 tumor suppressor genes in the pathogenesis of various human malignancies has been well established, yet little is known regarding plasma cell dyscrasias. In the present study, the loss of Rb1 protein expression, and the presence of Rb1 gene rearrangements as well as the presence of p53 somatic mutations (exons 5 through 9) were investigated in a panel of plasma cell dyscrasias, including 15 monoclonal gammopathies of undetermined significance (MGUS), 63 multiple myelomas (MM), and 18 plasma cell leukemias (PCL). In the same panel of cases, we established the frequency of ras oncogene mutations, the main genetic lesion associated with MM. We report that loss of Rb1 protein and p53 mutations are detectable in 34.7 and 9.8% of MM and PCL primary cases; no lesion was found in MGUS. In advanced stage MM, and PCL cases, Rb1 and p53 inactivation, as well as ras mutations were detected. Our findings show that Rb1 and p53 inactivation are associated with aggressive plasma cell dyscrasias, suggesting a role for these lesions in tumor progression rather than initiation.

Entities:  

Mesh:

Year:  1994        PMID: 8182933

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  17 in total

1.  p53 gene mutations in multiple myeloma.

Authors:  R G Owen; S A Davis; J Randerson; A C Rawstron; F Davies; J A Child; A S Jack; G J Morgan
Journal:  Mol Pathol       Date:  1997-02

Review 2.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

3.  p53 mutations in multiple myeloma.

Authors:  S Paydaś; B Sahin; E Seyrek; S Zorludemir
Journal:  Mol Pathol       Date:  1997-12

4.  Multiple changes in oncogenes and tumor suppressor genes in human retinoblastoma.

Authors:  R O Howard
Journal:  Trans Am Ophthalmol Soc       Date:  1996

5.  Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.

Authors:  Jan B Egan; Chang-Xin Shi; Waibhav Tembe; Alexis Christoforides; Ahmet Kurdoglu; Shripad Sinari; Sumit Middha; Yan Asmann; Jessica Schmidt; Esteban Braggio; Jonathan J Keats; Rafael Fonseca; P Leif Bergsagel; David W Craig; John D Carpten; A Keith Stewart
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

6.  Refractory multiple myeloma with extramedullary plasmacytoma of the spleen and suspicious teratoma: a rare case report and literature review.

Authors:  Peipei Xu; Hong Chu; Xiaoyan Shao; Ying Jiang; Chaoyang Guan; Ming Chen; Bing Chen
Journal:  Int J Clin Exp Pathol       Date:  2021-04-15

7.  Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.

Authors:  Fazal Shirazi; Richard J Jones; Ram K Singh; Jianxuan Zou; Isere Kuiatse; Zuzana Berkova; Hua Wang; Hans C Lee; Samuel Hong; Larry Dick; Nibedita Chattopadhyay; Robert Z Orlowski
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-03       Impact factor: 11.205

Review 8.  Genetic events in the pathogenesis of multiple myeloma.

Authors:  W J Chng; O Glebov; P L Bergsagel; W M Kuehl
Journal:  Best Pract Res Clin Haematol       Date:  2007-12       Impact factor: 3.020

Review 9.  Homing behaviour of the malignant cell clone in multiple myeloma.

Authors:  I Van Riet; K Vanderkerken; C de Greef; B Van Camp
Journal:  Med Oncol       Date:  1998-09       Impact factor: 3.064

10.  Combined morphological and interphase fluorescence in situ hybridization study in multiple myeloma of Chinese patients.

Authors:  M H Ng; A Kan; Y F Chung; I H Wong; K W Lo; N W Wickham; K I Lei; J C Lee
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.